Oncology Drug– category –
-
Catchup News: HER2 ADC Special Report Part 1｜The Rise of Enhertu and Pharmacological Differentiation Driving the Second ADC Boom
Antibody-drug conjugates (ADCs) have emerged as one of the most exciting modalities in oncology. Among them, HER2-targeted ADCs have undergone a dramatic transformation with the arrival of Daiichi Sankyo and AstraZeneca’s Enhertu, sparki... -
Claudin18.2 ADC Development Part 0: Series Introduction
This series provides an in-depth review of the current landscape of Claudin18.2 (CLDN18.2)-targeted antibody–drug conjugates (ADCs) in gastric and gastroesophageal junction (GEJ) cancers. Structured into five parts, it covers pivotal cli... -
Transcription Factors and DNA Repair Collision: Mutagenesis and Neoantigen Formation as a New Strategy for Cancer Immunotherapy
Introduction: A New Relationship Between Transcription Factors and DNA Repair Recent cancer research has highlighted DNA replication errors and defects in repair mechanisms as central drivers of tumorigenesis. The mismatch repair (MMR) s... -
A New Challenge in Pancreatic Cancer Therapy ― The Promise of “Two Shots on Goal”
Introduction: Why Pancreatic Cancer Is So Difficult to Treat Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a dismal 5-year survival rate of about 10%. Three major challenges underlie this poor ... -
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Comprehensive Summary and Future Outlook
Trilogy Subtitles＋Series Summary Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generatio... -
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Beyond Immunotherapy Resistance③
Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design... -
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Beyond Immunotherapy Resistance②
Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design... -
Frontiers of Cancer Vaccines for KRAS-mutant Pancreatic Cancer — Beyond Immunotherapy Resistance①
Trilogy Subtitles Part 1: Biological Background of KRAS-mutant PDAC and Theoretical Basis of Cancer Vaccines Part 2: Clinical Advances in RNA Vaccines and the AMPLIFY-201 Trial Part 3: CAR-T Integration and Next-generation Vaccine Design...
1